Lucentis
Scope
Date
~
-
Bio & Pharma
Samsung Bioepis gets FDA OK for its interchangeable biosimilar
Byooviz, a biosimilar of the macular degeneration treatment Lucentis and made by South Korea’s Samsung Bioepis, has received official design...
Oct 25, 2023 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis sees greater market for Byooviz eye disease biosimilar
NEW YORK – Samsung Bioepis Co., a biopharmaceutical unit of South Korea’s top conglomerate Samsung, is one step ahead of its rivals in t...
Jul 18, 2022 (Gmt+09:00)
-
Biosimilars
Samsung Bioepis gets FDA approval for Lucentis biosimilar Byooviz
Samsung Bioepis Co., a leading South Korean biopharmaceutical company, has received approval from the US Food and Drug Administration for its Byoovi...
Sep 23, 2021 (Gmt+09:00)
-
Biosimilars
Samsung Bioepis gets nod for sale of ophthalmology biosimilar in Europe
South Korea’s biopharmaceutical company Samsung Bioepis Co. won approval from European authorities for sale of Byooviz, its ophthalmology bios...
Aug 23, 2021 (Gmt+09:00)
language